Clinical trial · Observational
Correlation Between Expression of Hormonal Receptors, Clinical Data, and Methylation Profile in Meningiomas (MethylRH-M)
Correlation Between Expression of Hormonal Receptors, Clinical Data, and Methylation Profile in Meningiomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research aims to explore the relationship between hormonal receptor expression and the clinical and histopathological characteristics of meningiomas. The underlying hypothesis is that hormonal receptor expression, as well as the methylation profile of their gene promoters, are associated with specific aspects of meningiomas and patients' clinical outcomes. The main objective is to study the correlation between the immunohistochemical expression of hormonal receptors and clinicopathological data. The secondary objectif is to study the correlation between the methylation profile of hormonal receptor gene promoters and their immunohistochemical expression.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Meningioma | Meningioma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- immunohistochemical expression of different hormonal receptors
- timeFrame
- up to 24 years after surgery
- description
- Evaluated on FFPE sections
Secondary outcomes (1)
- measure
- methylation profile of the promoters of hormonal receptor genes
- timeFrame
- up to 24 years after surgery
- description
- Methylation profile established from frozen tissue.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who underwent surgery for a meningioma at the University Hospital of Nancy between 2000 and 2022. Exclusion Criteria: * Patients who did not express their consent to participate in the study. * Patients with grade 2 or 3 meningiomas whose samples are no longer available or in insufficient quantity to perform an immunohistochemical study. * Patients with grade 1 meningiomas not selected by randomization. * Patients withdrawing their consent.
References
Publications (0)
Data not yet available